Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation. The biotech ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
A very bullish analyst move was the news generally responsible for Summit Therapeutics' (NASDAQ: SMMT) healthy mid-week stock price pop. The person behind the news was Evercore ISI pundit Cory Kasimov ...
Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues ... up competition involving weight-loss drugs. The Food and Drug Administration two years ...
DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback